Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

@inproceedings{Haas2014EfficacySA,
  title={Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin},
  author={Brigitte Haas and Nathan Eckstein and V{\'a}clav Pfeifer and Paul Mayer and Masja De Hass},
  booktitle={Nutrition & Diabetes},
  year={2014}
}
Prevalence of diabetes mellitus is inc6reasing, with a burden of 382 million patients worldwide at present (more than the entire US population). The International Diabetes Federation anticipates an increase up to 592 million patients by 2035. Another major problem arises from the fact that just 50% of patients with type 2 diabetes mellitus are at target glycaemic control with currently available medications. Therefore, a clear need for new therapies that aim to optimize glycaemic control… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
21 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Carcinogenicity risk assessment upports the chronic Ssfety of dapagliflozin, an inhibitor of sodium-slucose co-transporter 2, in the reatment of type 2 diabetes mellitus

  • TP Reilly, MJ Graziano, EB Janovitz, TE Dorr, C Fairchild, F Lee
  • Diabetes Ther 2014;
  • 2014

Nutrition & Diabetes

  • B Haas
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…